What is the mechanism of action of ibrutinib?

Ibrutinib is a kinase inhibitor used to treat adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). For adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion. For use in adult patients with Waldenströ macroglobulinemia (WM). For use in adult and pediatric patients 1 year of age and older with chronic graft-versus-host disease (cGVHD) after failure of one or more systemic therapies.

Ibrutinib is a small molecule inhibitor of Bruton tyrosine kinase (BTK). Ibrutinibforms a covalent bond with the cysteine u200bu200bresidue in the BTK active site, resulting in the inhibition of BTK enzyme activity. BTKis a signaling molecule for the Bcell antigen receptor(BCR) and cytokine receptor pathways. BTK's role in signaling through B cell surface receptors results in activation of pathways necessary for B cell trafficking, chemotaxis, and adhesion. Non-clinical studies have shown that ibrutinib inhibits malignant cell proliferation and survival in vivo as well as cell migration and substrate adhesion in vitro.

Ibrutinib also eliminates BtkBtk autophosphorylation at Tyr-223 An>'s full activation,this inhibition prevents downstream activation of theBCR pathway and subsequently blocks the growth, proliferation and survival of malignantB cells. There are generic drugs in Bangladesh, Laos and India, with different manufacturers, different specifications, and different prices. The price per box is about 1000 to 2000 more. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.